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Summary One hundred and eight patients with squamous cell carcinoma of the upper aerodigestive tract
(UADT) (T3, T4, NO-N3; 17% stage II, 54% stage III, 27% stage IV) were given three courses of
chemotherapy before any local treatment. The regimen consisted of cis-platinum 100mgm-2 on day 1 and 5-
fluorouracil 1000mgm-2 on days 2-6; drugs were administered by continuous infusion. The toxicity of this
protocol was acceptable, as 82% of the patients were able to receive the initially scheduled drug dose. The
overall response rate of 86.5% included a 35% rate of complete lesion regression. The effect of this regimen
on primary tumours was especially remarkable - 87.5% responses, including 47.5% complete responses.
Results for lymph node metastases were not as good - 66% responses, including 33% complete responses.
The best results were obtained for tumours of the oropharynx and hypopharynx; oral cavity lesions were the
most refractory. For those patients who were subsequently operated on, histological examination of the
surgical specimen either confirmed sterilization or demonstrated the persistence of small disease foci. After
local treatment, which consisted of radiotherapy alone for 69% of patients, the lesion control rate was 80%.
At 18 months follow-up, the survival rate for patients who achieved a complete response with chemotherapy
was significantly better than that for patients with a response of less than 50%.
Tumours of the upper aerodigestive tract (UADT)
have long been considered unresponsive to
cytotoxic chemotherapy (Greenberg, 1984). For
some time, methotrexate and bleomycin were
essentially the only effective chemotherapeutic
agents (Bertino et al., 1975; Carter, 1977). These
drugs were often used after local treatment (surgery
and/or radiotherapy) on disease recurrence or
metastasis, but results were generally disappointing.
Objective response rates were significantly improved
in the 1970s by the introduction of cis-platin, used
both alone and in combination with other drugs
(Jacobs et al., 1978). The highest response rates
were produced by induction chemotherapy given
before any local treatment (Glick et al., 1980).
Following the work of Al-Sarraf et al. (1979) and
Kish et al. (1982), we have treated UADT tumours
with an induction combination of cis-platinum
(CDDP) and 5-fluorouracil (5-FU) since 1983. Our
promising preliminary results (Thyss et al., 1985)
have now been confirmed by this more complete
investigation of 108 cases.
Materials and methods
Induction chemotherapy regimen
Treatment consisted in continuous infusion of
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CDDP 100mgm-2 on day 1 followed by 5-FU
1000mgm-2 from day 2 to day 6. The protocol
called for three courses per patient. The interval
between cycles was 10 days for the first 63 patients
(Dl=D17=D33); the interval for subsequent
patients was lengthened to 15 days
(Dl =D22=D43).
Criteriafor admissibility
All patients had histologically confirmed squamous
cell tumours of the UADT; none had been treated
previously or had metastatic disease, except
metastatic cervical lymph nodes. Patients were in
good general condition (WHO grade <2) and had
normal renal function (creatinine <15mgI1).
There was no upper age limit, but drug doses were
reduced 10% for every 5 years over 70 years of age.
Evaluation ofresponse
Before treatment, lesions were biopsied during
endoscopy under general anaesthesia for all
patients. Response was assessed by multiple
biopsies obtained under identical conditions 10 days
after the last chemotherapy course. The 4 patients
with tumours of the sinus or face were evaluated by
computed tomography. Response was defined using
the products of two perpendicular lesion diameters:
complete response (CR) corresponded to disap-
pearance of all clinically visible or palpable lesions;
partial response (PR) was defined as tumour
regression over 50%; no response (NR)
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corresponded to tumour regression of 50% or less,
stabilization, or progressive disease. The response
of palpable lymph nodes was evaluated with the
same criteria by physical examination and
ultrasonography.
After completion of the induction chemotherapy
program, all 103 patients for whom response was
evaluable were given local-regional treatment: 70
patients were treated by radiotherapy alone (65-70
Gy), 33 patients underwent uni- or bilateral surgical
resection completed by irradiation of the tumour
bed and nodal regions (55Gy). After loco-regional
treatment, patients were examined a third time to
determine the extent of control obtained by the
complete therapy program. For patients who
underwent surgery after chemotherapy, response
was evaluated by histological examination of the
surgical specimen.
Patients
A total of 108 patients (94 men, 14 women) were
entered in the study; mean age was 61 years (range
36-82). Table I lists patient data by TNM criteria.
Most patients were T3-T4 (n=84, 78%). The
distribution between NO (54 patients) and N2, 2, 3
(54 patients) was identical. The distribution by
UICC criteria was as follows: 18 stage II (17%); 61
stage III (56%); 29 stage IV (27%). No patient had
distant metastasis. The sites of primary tumours
were as follows: 20 oral cavity (18%), 50
oropharynx (40%), 30 larynx or hypopharynx
(28%), 4 facial sinuses (4%), 4 rhinopharynx (4%).
Protocolfeasibility
The treatment protocol proved feasible because the
doses actually administered were greater than or
equal to 90% of the planned dose for 88 patients
(82%). Moreover, 90 patients (83.5%) received all
three chemotherapy courses, and the interval
between cycles was as protocol in most cases. The
Table I Induction chemotherapy with cis-platinum and
5-fluorouracil.
Patient distribution by tumour size and node involvement
Ti T2 T3 T4 Total
NO - 18 31 5 54
NI 9 21 1 31
N2 - 1 8 1 10
N3 3 3 6 1 13
Patient distribution by UICC stage
Stage II III IV
No. patients 18 61 29
Percentage 17 56.5 27
interval between cycles 1 and 2 was 10 to 15 days
for 81 patients (76%). For the 90 patients who
received all three courses, the interval between
cycles 2 and 3 had to be prolonged for more than
15 days for only 26 patients (28.5%).
Results
Overall results
Response was evaluable for only 103 of the 108
patients; 4 patients died after the first course and 1
refused to be evaluated. Taking all lesions into
account (primary tumour plus any involved nodes),
an objective response was obtained in 89/103
patients (86.5%): there were 36 CR (35%), 53 PR
(51.5%) and only 14 NR (13.5%).
Resultsfor primary tumours
As shown by Table II, an objective response was
obtained for the primary tumour in 87.5% of cases
(47.5% CR); only 12.5% of patients were classed
NR.
Analysis of response as a function of tumour size
revealed that a CR was achieved for all 3 TI
patients (100%), for 21/31 T2 patients (68%), and
for 23/62 T3 patients (37%). Although the size of
the tumour at initial presentation appears to affect
achievement of a CR, 2 of the seven T4 patients
achieved a tumoral CR.
Results by anatomic site
Table III reveals that the percentage of CR was
particularly high for patients with lesions of the
oropharynx (53%) or hypopharynx (48%). Oral
cavity tumours were more refractory to this type of
chemotherapy (only 31.5% CR).
Resultsfor metastatic lymph nodes (Table IV)
As is often the case, the quality of clinical response
was not as good for metastatic lymph nodes as for
Table II Results on the primary tumour for 103
evaluable patients.
Tumour size
Ti T2 T3 T4 Total %
Complete
response 3/3 21/31 23/62 2/7 49/103 47.5
Partial
response - 9/31 30/62 2/7 41/103 40
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Table III Results by anatomic site.
Larynx-
Oral cavity Oropharynx hypopharynx
Complete
response 6 (31.5) 24 (53) 15 (48)
Partial
response
(>50%) 9 (47.5) 17 (38) 12 (39)
No response 4 (21) 4 (9) 4 (13)
Table IV Results on lymph node metastases.
NJ N2 N3 %
Complete
response 11/24 3/9 1/12 33
Partial
response
(>50%) 5/24 5/9 5/12 33
No response 8/24 1/9 6/12 33
primary tumours. Even so, the overall response rate
of 66% (including 33% CR) is particularly high. A
CR was obtained for 11 of the 24 NI patients
versus only 1 of the 12 N3 patients.
Local control after completion ofthe treatment
After induction chemotherapy, 19 patients were
treated locally by surgery alone, 69 by radiotherapy
alone, and 13 by surgery followed by radiotherapy.
In all, 101 patients received the complete planned
treatment: 80 were considered controlled, 13 still
had progressive disease, and 8 died during the
treatment program (4 during chemotherapy, 4
postoperatively).
Evaluation ofthe histologic response
The Micheau classification (Micheau & Richard,
1975) was used to evaluate tumour regression for
the 31 patients who underwent surgery immediately
after induction chemotherapy. For the 6 patients
who had been classed CR, histologic examination
of the surgical specimen confirmed CR status (IlIc)
in 1 case, revealed intra-epithelial lesions in 2 cases,
sterilization of the greater part of the specimen in 2
cases, and nearly complete sterilization (Ilb) in the
last 2 cases.
The histology report for thl 21 patients who had
been clinically classed PR indicated complete
sterilization (II1c) in 5 cases, sterilization of a major
portion of the specimen (IIIb) in 4 cases, consider-
able sterilization (Ilb) in 5 cases, and persistence of
active lesions in 7 cases. All 4 of the NR patients
who underwent surgery still had progressive disease.
Toxicity
Most of the patients experienced the nausea and
vomiting commonly observed with treatments
including cis-platinum. Venous damage (including
pigmentation) attributable to 5-FU was also
common, and was only partially prevented by
keeping the infused limb in the dark. Electrolyte
disorders such as hypokaliemia and hypo-
magnesemia were common; systematic monitoring
is therefore warranted for detection and correction.
Disturbances in appetite, including severe anorexia,
were frequent during chemotherapy.
Haematological toxicity was evaluable for 307
cycles using WHO criteria: there were 262 grade 0
cycles (85.5%), 29 grade I or II (9.5%), and 16
grade III or IV (5%). Evaluation of gut toxicity
(mucositis and/or diarrhoea) with WHO criteria
gave the following results: 245 grade 0 cycles
(80%), 50 grade I or 11(16%), and 12 grade III or IV
(4%). Most gut toxicity consisted of oral mucositis.
The frequency of mucositis was reduced when the
10 day interval between cycles was increased to 15
days.
Other toxic manifestations included a transient
rise in plasma creatinine, which regressed after
several days for 2 patients, and balanitis for 2 other
patients. Eight patients had particularly severe
asthenia (6 of them were aged >70 years). Four
deaths were attributable to the chemotherapy
regimen, but all patients (aged 67, 70, 71 and 74
years) had significant medical complications:
decompensated alcoholic cirrhosis (1 case),
myocardial infarction 5 years earlier (1 case), severe
arteriosclerosis of the lower limbs requiring
amputation (2 cases).
Finally, in contrast to certain recent reports
(Slotman et al., 1984) of an increased incidence of
distant metastasis in patients treated by induction
chemotherapy during the 12 months following
treatment, we did not observe any case of visceral
metastasis after a median follow-up period of 1
year.
Discussion
Induction chemotherapy has several theoretical
advantages: Sterilization of cells that might be
disseminated by surgery, reduction of the size of
large tumours allowing easier local treatment, in
vivo evaluation of tumour chemosensitivity. In
addition, the rate of response to chemotherapeutic
agents is higher for patients who have never been758 A. THYSS et al.
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Figure 1 Actuarial survival curves at 18 months for
patients in complete clinical remission after
chemotherapy ( ) and non-responders (-
P<0.001.
treated before than for patients who have already
received local treatment: the local vascularization of
these last patients' tumours is often reduced, their
nutritional status is frequently poor, and they are at
greater risk for occult metastasis owing to longer
time interval before systemic treatment is started.
During the past few years, induction chemotherapy
trials have therefore been conducted for advanced
upper aerodigestive tract tumours which have a
high rate of loco-regional recurrence (over 60%)
and distant metastatis (20%-30%) (Probert et al.,
1978). While results with initial trials using
methotrexate were controversial (Ervin et al., 1980;
Fazekas et al., 1980), various multidrug regimens
proved more effective, and frequent complete
responses were obtained. CDDP combined with
bleomycin (BLM) (Hong et al., 1979) and/or vinca
alkaloids and/or methotrexate (MTX) are among
the most effective associations, with data indicating
objective responses in 48%-100% of patients so
treated (Brown et al., 1980; Randolph et al., 1978).
In an earlier study covering 85 patients, we
obtained objective lesion regression in 56.6% of
patients after systemic administration of 2 courses
of an induction chemotherapy regimen including
vincristine (VCR), BLM, MTX and CDDP; this
rate rose to 76.5% for patients who received the
same regimen by an intra-arterial route (Demard et
al., 1985).
As first demonstrated in experimental animal
models (Schabel et al., 1979), associating 5-FU with
CDDP considerably potentiates the action of both
drugs. Since 1980, several studies have been
performed on UADT tumours using different
doses, modes of administration, and number of
courses. Rooney et al. (1985) achieved best results
with 3 cycles of a regimen including CDDP
100mgm-2 day 1 followed by a continuous 120h
infusion of 5-FU 1000mg24h-1. While their
overall response rates were similar for 2 and 3
courses (respectively 88% and 93%), the rate of
complete regressions was clearly in favour of 3
courses (54% versus only 19% for 2 courses;
P=0.00,4).
Lacau et al. (1985), using a CDDP, 5-FU, BLM
combination, observed a significant increase in the
percentage of complete responses between the 2nd
and 3rd courses.
Our results are comparable; our overall response
rate of 86.5% included 35% complete responses.
Analysis of results confirmed that the
chemotherapy regimen used was more effective on
primary tumours than on metastatic lymph nodes:
85% response rate for primary tumours, including
47% complete responses (the quality of response
decreased as the tumour size increased) versus only
66% for lymph nodes (33% complete responses).
The anatomical site of lesions also a fected
results: more complete regres'ions were obtained
for lesions of the oropharynx and hypopharynx
than for oral cavity tumours (53% versus 31.5%).
The difference between clinical and histological
evaluation of tumour response warrants mention.
While it is not surprising that minimal histological
lesions were detected in certain patients clinically
graded CR, the fact that 5 of the twenty-one PR
patients no longer had any histological lesions is
more remarkable. This is probably due to the fact
that persistence of minimal anomalies at the initial
tumour site creates doubt as to the complete nature
of clinical response. On physical examination, CR
and PR patients were actually very similar when
compared with respect to their histological status.
Administration of 3 courses of our multidrug
regimen proved feasible, despite the unquestionable
problem of toxicity (especially gut, mucosal and
venous toxicity), which can be reduced to a
minimum with adequate hydration, correction of
electrolyte disorders, and appropriate patient
renutrition. Valuable information allowing pre-
diction of toxic manifestations can also be obtained
by pharmacokinetic studies (Thyss et al., 1985a, b).
The most important question at present is
evaluation of the effect of such chemotherapy on
prognosis, in other words on the disease-free
interval and on survival. At short term, induction
chemotherapy improved the local control rate:
80/101 evaluable patients in our series were
controlled after subsequently undergoing surgery
alone (19 patients), radiotherapy alone (69
patients), or surgery followed by irradiation (13
patients). These figures reflect a marked reduction
in the use of certain major surgical procedures
following response to induction chemotherapy.
When a CR is obtained for a patient initially
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(transmaxillary bucco-pharyngectomy, subtotal
glossectomy, laryngectomy or total pharyngeco-
laryngectomy), the treatment strategy may be
changed in favour of irradiation. This is true for
increasing numbers of patients. This advantage
insofar as it concerns patient comfort and
functional results is decisive in our opinion, and
sufficient to justify use of this induction chemo-
therapy regimen even though it has not yet been
proved that it improves the disease-free interval or
survival.
Several publications have reported an
improvement in both the disease-free interval and
survival for patients administered induction
chemotherapy, but comparisons were made with
historical controls (Ervin et al., 1984). With a
VCR/BLM/MTX/CDDP combination, we
demonstrated that the duration of survival was
significantly longer for patients who achieved a CR
or PR (Demard et al., 1983). CDDP plus 5-FU has
given results which confirm this benefit (Ensley et
al., 1984). Moreover, certain studies have shown
the CDDP/5-FU regimen to be superior to
CDDP/VCR/BLM; they have also revealed the
benefits of 3 courses rather than only 2 courses for
survival (Rooney et al., 1985).
Although our follow-up period is still too short
for any definitive conclusions to be drawn, there is
a statistically significant difference in survival at 18
months in favour of patients who achieved a CR as
opposed to nonresponders (Figure 1; P<0.001, log
rank test). Recent randomized trials, and
particularly that of the EORTC Head and Neck
Group (Demard et al., to be published), have not
shown any differences between these two groups of
patients, but none of them has used this CDDP/
5-FU combination, which gives much better results
than other protocols. New controlled trials are thus
justified and warrant immediate attention.
The authors wish to thank Nancy Rameau for translation
and preparation of the manuscript.
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